NCT07550049Not yet recruiting
Comprehensive Oncogenomic Mapping and Exploration in Thoracic and Head & Neck Oncology
COMETH Study: Comprehensive Oncogenomic Mapping and Exploration in Thoracic and Head & Neck Oncology
Source: ClinicalTrials.gov · Last updated 24 Apr 2026
Brief summary (registry, in English)
This is an ancillary laboratory study to collect and bank blood and tissue samples. The biospecimens collected for this study will be invaluable for future research into predictive biomarkers and genomic alterations and their correlation with clinical outcomes.
- Status (registry)
- Not yet recruiting
- Study type
- Observational
- Enrollment
- 110 (estimated)
- First submitted
- 17 Apr 2026
- Start date
- Apr 2026
- Primary completion date
- Apr 2029
- Lead sponsor
- University of Kansas Medical Center
- Diseases
- Head and neck cancer, Mesothelioma, Lung cancer
- NCT number
- NCT07550049
What you commit to
- Study type: Observational
- Planned participants: 110
- From Apr 2026 to the primary completion date, Apr 2029
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Diagnosed with a psychiatric illness or is in a social situation that would limit compliance with study requirements
- Presence of a condition(s) or diagnosis, either physical or psychological, or physical exam finding that precludes participation.
- Advanced stage (IIIB to IV) non-small cell lung cancer with actionable mutations
- Active viral infection (Hep C or B) requiring anti-viral therapy in the last 28 days. HIV patients on stable on anti-viral therapy able to receive therapy for the cancer are eligible to participate.
- Second malignancy that requires systemic treatment at the time of consent
Other
- Active use of prednisone equivalent to more than 10mg/day
Who the study is looking for
- Ability of participant to understand this study, and participant willingness to sign a written informed consent. NOTE: Remote consenting allowed per IRB policy.
- Stated willingness to comply with all study procedures and availability for the duration of the study
- Males and/or females age ≥ 18 years
- Diagnosis of one of the following:
- Advanced stage (IIIB to IV) non-small cell lung cancer (all types including mixed histology, without actionable mutations)
- Extensive-stage small cell lung cancer that are treatment naïve that will receive immunotherapy and chemotherapy
- Recurrent or metastaƟc squamous cell head and neck cancers, squamous cell, HPV posiƟve or HPV negaƟve, treatment naïve that will start immunotherapy and chemotherapy
- Malignant pleural mesothelioma that will be treated with immunotherapy and chemotherapy
- Eligible to receive chemotherapy (plaƟnum based) with an immune checkpoint inhibitor (single or double agents).
- Able to provide consent to obtain a blood sample, prior future genomic research of their samples.
- Planning to start therapy in the next 28 days.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.